MGMT and central nervous system cancer: The median overall survival for grade III glioma patients with MGMT promoter-methylation was 171.0 (95% CI: 115.4–226.6) months compared to just 44.3 (95% CI: 39.3–49.3) months in those without the mutation (p = 0.006).